Eros Di Bona

Bassano Del Grappa, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 38 publications

Iptacopan monotherapy resulted in increased hemoglobin level in patients with PNH and hemoglobin ≥10 g/dL after anti-C5 therapy.

Iptacopan monotherapy resulted in increased hemoglobin level in patients with PNH and hemoglobin ≥10 g/dL after anti-C5 therapy.

Journal: HemaSphere

Published: February 06, 2026

Prophylaxis and management of thromboembolism in pnh patients: an italian survey.

Prophylaxis and management of thromboembolism in pnh patients: an italian survey.

Journal: Annals of hematology

Published: February 03, 2026

Real life use of ravulizumab in Italian patients with paroxysmal nocturnal hemoglobinuria: evidence from the REACTION observational study.

Real life use of ravulizumab in Italian patients with paroxysmal nocturnal hemoglobinuria: evidence from the REACTION observational study.

Journal: Annals of hematology

Published: August 01, 2025

Oral iptacopan monotherapy in paroxysmal nocturnal haemoglobinuria: final 48-week results from the open-label, randomised, phase 3 APPLY-PNH trial in anti-C5-treated patients and the open-label, single-arm, phase 3 APPOINT-PNH trial in patients previously untreated with complement inhibitors.

Oral iptacopan monotherapy in paroxysmal nocturnal haemoglobinuria: final 48-week results from the open-label, randomised, phase 3 APPLY-PNH trial in anti-C5-treated patients and the open-label, single-arm, phase 3 APPOINT-PNH trial in patients previously untreated with complement inhibitors.

Journal: The Lancet. Haematology

Published: January 13, 2025

Oral Iptacopan Monotherapy in Paroxysmal Nocturnal Hemoglobinuria.

Oral Iptacopan Monotherapy in Paroxysmal Nocturnal Hemoglobinuria.

Journal: The New England journal of medicine

Published: March 13, 2024

Real-world efficacy and safety of luspatercept and predictive factors of response in patients with lower risk myelodysplastic syndromes with ring sideroblasts.

Real-world efficacy and safety of luspatercept and predictive factors of response in patients with lower risk myelodysplastic syndromes with ring sideroblasts.

Journal: American journal of hematology

Published: January 22, 2023

The long-acting anti-C5 ravulizumab results in C3 binding to PNH red cells similar to its parental molecule eculizumab.

The long-acting anti-C5 ravulizumab results in C3 binding to PNH red cells similar to its parental molecule eculizumab.

Journal: British journal of haematology

Published: October 31, 2022

Management of infection in PNH patients treated with eculizumab or other complement inhibitors: Unmet clinical needs.

Management of infection in PNH patients treated with eculizumab or other complement inhibitors: Unmet clinical needs.

Journal: Blood reviews

Published: July 20, 2022

SARS-CoV-2 vaccination in patients with paroxysmal nocturnal hemoglobinuria: An Italian multicenter survey.

SARS-CoV-2 vaccination in patients with paroxysmal nocturnal hemoglobinuria: An Italian multicenter survey.

Journal: American journal of hematology

Published: March 10, 2022

Corrigendum to "Venetoclax in combination with hypomethylating agents in previously untreated patients with acute myeloid leukemia ineligible for intensive treatment: a real-life multicenter experience" [Leukemia Res. 114 (March 2022) 106803].

Corrigendum to "Venetoclax in combination with hypomethylating agents in previously untreated patients with acute myeloid leukemia ineligible for intensive treatment: a real-life multicenter experience" [Leukemia Res. 114 (March 2022) 106803].

Journal: Leukemia research

Published: February 27, 2022

Venetoclax in combination with hypomethylating agents in previously untreated patients with acute myeloid leukemia ineligible for intensive treatment: a real-life multicenter experience.

Venetoclax in combination with hypomethylating agents in previously untreated patients with acute myeloid leukemia ineligible for intensive treatment: a real-life multicenter experience.

Journal: Leukemia research

Published: October 24, 2021

COVID-19 in patients with paroxysmal nocturnal haemoglobinuria: an Italian multicentre survey.

COVID-19 in patients with paroxysmal nocturnal haemoglobinuria: an Italian multicentre survey.

Journal: British journal of haematology

Published: May 26, 2021

Showing 1-12 of 38

Last Updated: 09/26/2026